Lidocaine Patches Market to register high demand rate Worldwide: Top manufactures, challenges and Drivers by 2026

Lidocaine is an aminoethylamide local and topical anesthetic medication, causing temporary numbness or loss of sensation in the area of application. Lidocaine blocks the voltage-gated sodium channels of nerve membranes, thereby preventing the generation and conduction of nerve impulses and providing analgesic relief. Lidocaine patch 5% comprises a soft, stretchy adhesive patch containing 5% lidocaine for the topical treatment of pain associated with Post Herpetic Neuralgia (PHN). The first FDA approved transdermal lidocaine patch was Lidoderm, in 1999, by Endo Pharmaceuticals Inc. Increasing incidence of back and neck pain is the key factors driving growth of the market. However, availability of alternatives for the pain management such as other pain killer drugs are expected to restrain growth of the lidocaine patches market growth.

Increasing incidence of the shingles is expected to fuel growth of the lidocaine patches market during the forecast period. Shingles, also known as herpes zoster, leads to the chronic pain known as Post Herpetic Neuralgia (PHN) in which lidocaine patches are used. According to Centers for Disease Control and Prevention (CDC), January 2018, an estimated one third of the total U.S. population develops shingles during their lifetime, which suggests nearly 1 million Americans experiences shingles infection annually. Furthermore, CDC estimated that around 10 to 15% people with shingles infection experience PHN.

Download The PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1805

Lidocaine Patches Market Dynamics

Increasing number generic approved product in the market are expected to augment the lidocaine patches market growth. Patent expiry of Endo Pharmaceuticals for Lidoderm offers growth opportunity for market players to develop generic version of the lidocaine patch. For instance, in 2015, Mylan Pharmaceuticals, Inc., launched the generic version of Endo Pharmaceutical’s Lidoderm in the U.S. market. In 2014, Galen US Incorporated receive FDA approval for Synera, lidocaine and tetracaine topical patch for domestic use. Moreover, companies are introducing advanced technologies in lidocaine patches in order to maintain leading position in market, For instance, in 2016, Gregory Pharmaceutical Holdings, Inc. launched Lidocare, which is first and only patch that is water-free. Lidocare is the new over-the-counter/non-prescription lidocaine pain patch and the technology is under the patenting process. In February 2018, Sorrento Therapeutics, Inc., a subsidiary of Scilex Pharmaceuticals Inc., received U.S. FDA approval for ZTlido 1.8%, with the company’s proprietary adhesion technology. Furthermore, companies are also conducting clinical trials for expanding the application of lidocaine patch for disease and conditions such as Endo Pharmaceuticals, Inc., is conducting clinical trial for the use of lidocaine patch in osteoarthritis, chronic lower back pains, Carpal Tunnel Syndrome etc.

Lidocaine Patches Market – Regional Analysis

Regional segmentation of lidocaine patches market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America lidocaine patches market holds dominant position, owing to large number of product launches by the regional players and strategic collaborations among market players to introduce their product in regional market. For instance, Galen’s acquisition of Synera patch, a product of Nuvo Research, to commercialize the product in U.S. lidocaine patches market. Furthermore, reimbursement policies in North America related to lidocaine patch are supporting the market growth. Moreover, Asia Pacific Lidocaine Patches Market is expected to witness fast growth attributed to increasing incidence of herpes zoster in these region and lack of preventive vaccination against shingles, which is expected to boost the lidocaine patches market growth.

Lidocaine Patches Market – Competitive Analysis

This market is highly fragmented, with the presence of Mylan Pharmaceuticals Inc., Endo Pharmaceutical Inc., Teva Pharmaceutical, Inc., Teikoku Pharma USA, Hisamitsu Pharmaceuticals Co. Inc., Galen US Inc., Sorrento Therapeutics, Inc. and Actavis Labs UT Inc. market players.

Manufacturers are focused on acquisition of complementary companies to enter the market with advanced products in lidocaine patches. For instance, in 2013, Galen entered into a product acquisition and license agreement with Nuvo Research Inc. pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain. Acquisition offers exclusive rights to market and sell Nuvo’s Synera patch throughout the U.S. for its current indication. Under these agreement Nuvo Research Inc. will receive royalties of 10% of net sales.

Pompe Disease Therapeutic Market Overview, Manufacturing Cost Structure Analysis, Growth Opportunities

Pompe disease is an inherited Lysosomal Storage Disorder (LSD) caused by a deficiency of enzyme acid named alpha-glucosidase (GAA). This causes the glycogen to accumulate in different kinds of tissues, primarily into smooth muscles, skeletal muscles and cardiac muscle. It leads to muscle weakness, respiratory problems, and may also affects the liver and heart. Pompe disease is inherited as an autosomal recessive genetic trait. There are three major types of pompe disease, which differ in severity and appear at different age, these types are known as classic infantile-onset, which starts within a few months of birth, non-classic infantile-onset Pompe disease- usually appears by age 1, and late-onset type of Pompe disease that may shows the symptoms later in childhood, adolescence, or adulthood. Pompe disease therapeutic market can exhibit immense growth potential due to presence of limited number of manufacturers, which can significantly enhance and expand their business potential and scope in this market.

Pompe Disease Therapeutic Market Taxonomy:

By Therapy Type:

  • Gene Therapy

  • Enzyme Replacement Therapy (ERT)

  • Chaperone-Advanced Replacement Therapy (CHART)

By Administrational Route:

  • Oral

  • Parenteral

By Patient Type:

  • Infants

  • Adults

Download The PDF Brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1316

Considering the public health problems, government is taking continuous initiatives in promoting and advancing the development of innovative products for the prevention and diagnosis or treatment of rare diseases or conditions such as Pompe disease. For instance, in 2015, Orphan Product Grants Program funded 18 new grant awards from 92 grant applications and provided funding and support to around 67 ongoing clinical study projects related to rare disease. Furthermore, initiatives from the governments of economies such as Sweden, the Netherlands, and South Korea that focus on approving guidelines for the reimbursement of individuals undergoing enzyme replacement therapy (ERT) are also expected to boost growth of the pompe disease therapeutic market in near future.

Increasing prevalence of pompe disease in many economies is expected to have a lucrative opportunities for pharmaceutical manufacturers to come with a tailored solution for diagnosis and treatment of disease. For instance, according to United Pompe Foundation (UPF), 2017, the estimated frequency occurrence of Pompe disease may vary among different ethnic groups and nationalities: in Holland: 1 in 40,000 (Adults: 1 in 57,000; Infantile: 1 in 138,000), Southern China and Taiwan: 1 in 50,000 births, African-Americans: 1 in 14,000 births and Caucasian: 1 in 100,000 suffer from pompe disease. Gene therapy and enzyme replacement therapy may be highly effective at reducing clinical manifestations of this rare disease. Currently, there are two commercialized products in enzyme replacement therapy, which are Myozyme for the treatment of infants and children with Pompe disease and Lumizyme for late-onset non-infantile Pompe disease. Furthermore, various pipeline products in phase 3 (NeoGAA GZ402666 (Sanofi), AT-982 (Audentes therapeutics)) and in phase 2 (BMN 701(Biomarin)) clinical trial are also expected to create a meteoric growth in this market during the forecast period. However, the high cost associated with the treatment and long duration of the treatment are the factors restraining growth of the pompe disease therapeutic market. For instance, according to a research paper published by Harvard School, in 2016, Lumizyme accounted for US$ 100,000 per year for children and US$ 300,000 per year for adult treatments.

Increasing investments in research and development by manufacturers is expected to propel the market growth

Manufacturers are focusing on finding new solutions by expanding their pipeline to cater the demand for pompe disease therapeutics market. For instance, in September, 2017, Avrobio Inc. expanded their products pipeline with gene therapy to treat pompe disease by utilizing a proprietary lysosomal targeting sequence to deliver high levels of enzyme to lysosomes. Furthermore, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. This novel treatment paradigm consists of ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P) to enhance uptake, co-administered with AT2221, a pharmacological chaperone.

Key players operating in the pompe disease therapeutic market include Amicus Therapeutics, Inc., Valerion Therapeutics, LLC, Sanofi S.A., Oxyrane, and Sangamo Therapeutics, Inc.

Click To Continue Reading On Pompe Disease Therapeutic Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Clinical Trial Supply and Logistics Market Positive long-term growth outlook 2018-2026

Continuous emphasis by the manufacturers towards balancing shipment and supply costs, optimizing production and packaging and minimizing overage and avoiding shortages, are propelling the demand for efficient solutions for clinical trial supply and logistics. Technological advancements will also drive the growth in clinical trial supply and logistics market, providing efficient planning and real-time data analysis to improve supply chains mid-trial. Drug pooling for multi-trial programmes will also augment the demand for regional depot network with strong transport networks to trial sites.

Market Dynamics

Increase in number of registered clinical trials across the regions is also expected to spur the demand of clinical trial supply and logistics market during the forecast period. Various online sources suggest that the Brazil holds the second most registered clinical trials among the BRIC (Brazil, Russia, India and China) countries, with a share of approximately 2% of the global volume. Furthermore, vendors are also focussing on launching different clinical programs to market their services and attract more clients and government to partnership with them. For instance, in June 2018, Bionical Group Ltd launched Bionical-Clinical Early Access Programs (EAP) which connect established and successful Clinical Research Organization to support large and small scale Pharma and Biotech industries enabling, appropriate treatment access to patients in desperate need.

Download The PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1798

Key features of the study:

  • This report provides in-depth analysis of the clinical trial supply and logistics market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2016 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global clinical trial supply and logistics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Clinical Trial Supply and Logistics Market Regional Outlook

On the basis of region, the global clinical trial supply and logistics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to hold a dominant position in this market, owing to the adoption of technologically advanced products, well established regulatory agencies, and presence of major Contract Research Organizations (CRO’s) and biopharmaceutical company’s hubs. Moreover, factors such as improved healthcare facilities and better reimbursement scenario are also driving growth of clinical trial supply and logistics market in this region.

Some of the key players operating in the global clinical trial supply and logistics market include Catalent Pharma Solutions, Inc., Almac Group, Movianto, Patheon, Inc., PCI Pharma Distribution, Sharp Packaging Distribution, PAREXEL International Corporation, Marken, KLIFO A/S, and Biocair.

Digital Fluoroscopy System Market Share, Revenue Analysis And Growing Key Players

Digital fluoroscopy is form of X-ray that enables technician to visualize deep structures of the body. Digital fluoroscopy provides detailed images of different organs such as intestine, cardiac muscle, bladder, and stomach. Conventional X-ray records images to a film, while digital fluoroscopy helps in recording a series of images to the computer. Digital fluoroscopy is majorly used to check and evaluate the gastrointestinal tract, which includes stomach, esophagus, duodenum and the colon. Furthermore, it is used to diagnose tumors, ulcers, hiatal hernias, scarring, reflux, inflammation, and blockages. It examines and evaluates kidney function in venography and angiography procedures (placement of tubes in veins and arteries) and pain management procedures (nerve root blocks). Procedures that use fluoroscopy are orthopedic surgery, podiatric surgery, angiography, placement of Peripherally Inserted Central Catheter (PICC), placement of weighted feeding tube in the duodenum, urological surgery, cardiology, discography, lumbar puncture, and modified barium swallow study.

High cost of devices and novel procedures in pipeline, which may provide better result than fluoroscopy are restraining growth of the digital fluoroscopy system market. For instance, endoscopic retrograde cholangioscopy procedure using spy glass rather than digital fluoroscopy to detect bile duct stones has completed phase three clinical trials in 2017, this is sponsored by Boston Scientific Corporation, a leading medical device company.

Download The PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1782

Digital Fluoroscopy System Market Dynamics:-

Increasing number of orthopedic surgeries and angiography are major drivers for growth of global digital fluoroscopy system market. According to a survey conducted by American Academy of orthopedic surgeons, in 2014, more than six million patients were reported for knee replacement surgeries, more than three million patients were reported for hip replacement surgeries and more than four million patients were reported for spinal fusion surgeries. Moreover, innovation in fluoroscopy devices is expected to fuel digital fluoroscopy system market growth. For instance, in 2015, Care Stream Health Corporation launched Carestream DRX Excel and Carestream DRX Excel Plus, this devices enhance workflow using fluoroscopy. These devices records both fluoroscopy and radiography sequences. Approvals of new products by regulatory bodies are also driving growth of the digital fluoroscopy system market size. For instance, in April 2018, Afga Healthcare received Food and Drug Administration (FDA) approval for DR multipurpose imaging system. It is a solution for digital radiography, digital fluoroscopy, and advanced clinical applications such as use of image processing software ‘DYNAMIC MUSICA’ for both static and dynamic (moving) images.

Digital Fluoroscopy System Market Regional Analysis:-

North America is expected to lead digital fluoroscopy system market due to high prevalence of medical conditions such as varicose veins, pulmonary embolism, peripheral artery disease, and pulmonary embolism. According to a study conducted by Center for Disease Control and Prevention (CDC), in 2016, more than 8.5 million people in U.S. are suffering from peripheral artery disease, out of which more than 12% are geriatric population. According to a survey conducted by National Institute of Health (NIH), in 2016, more than 40 million people in the U.S. are diagnosed with varicose veins. Such high prevalence of diseases can drive growth of the North America digital fluoroscopy system market as digital fluoroscopy system is used for diagnosis of these diseases.

Digital Fluoroscopy System Market Key Players:-

Key players operating in global digital fluoroscopy system market include Philips Healthcare, GE Healthcare, Siemens Health, Toshiba Medical Systems, Shimadzu Medical, Ziehm Imaging, Hitachi Medical Systems, Orthoscan Inc. and Hologic Corporation.

Pediatric Nutrition Market – Global Industry – Key Players, Economic Impact, Cost and Revenue from 2018-2026

Pediatric nutrition refers to the nutritional products given to infants or children as a sole source of nutrition or supplement. These products support physical and mental growth of children, in turn supporting balanced growth in their formative years, from infancy to adolescence. The usage of  these products is critical in cases of premature birth or babies suffering from severe allergies such as lactose intolerance. In premature birth, baby can’t be directly breastfed and hence, these products are the sole source of nutrition till they get switched to breastfeeding. According to Centers for Disease Control and Prevention (CDC), 2016, around 10% (1 in every 10) of births recorded were premature in the U.S. Moreover, globally, every year around 15 million births are premature, according to the World Health Organization (WHO). Products are also being developed for infants suffering from certain inborn diseases such as maple syrup urine disease or phenylketonuria.

Increasing demand for nutritional products in Asia Pacific is expected to boost growth of the pediatric nutrition market

Asia Pacific is home to two of the most populous countries in the world, India and China. Number of births in these countries is also among the highest, every year. Moreover, in October 2015, China abolished its one-child policy, which in turn is expected to increase the birth rate in China. According to World Bank, in India, crude birth rate (birth per 1,000 people) was recorded to be 19 in 2015, which was much higher as compared to developed economies such as the U.S., U.K., Germany, France, and Italy which recorded crude birth rate of 12, 12, 9, 12, and 8, respectively. Significant year-on-year increase in the crude birth rate in India, is expected to increase in the number of total births in the country in the near future.

Request For Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/1308

Furthermore, Companies such as Mead Johnson Nutrition have operated with very high gross margins accounting for 64.2%, 64.3%, and 61.4% in 2016, 2015, and 2014, respectively. This in turn, indicates lucrative opportunity for market players in this market, which in turn is increasing the entry of large players. Due to the high gross margins, new manufacturers are competing with leading players by selling their products at a reasonable but profitable price.

The global pediatric nutrition market was valued at US$ 35,211.6 million in 2016 and is expected to witness a CAGR of 6.4% over the forecast period (2017 – 2025).

Lactose intolerance, allergy to cow’s protein milk, maple syrup urine disease, phenylketonuria, and insulin resistance are some of the most common health complications faced by infants and children. These children require special nutrition, which can be provided by nutritional products. Mead Johnson Nutrition (acquired by Reckitt Benckiser Group Plc) developed a separate category of products specifically designed for children suffering from such diseases. These products include Mead Johnson BCAD, for children suffering from maple syrup urine disease and Mead Johnson PhenylFree, for children suffering from phenylketonuria. Other players such as Nestle S.A. and Abbott Laboratories also sell product for children with special needs. Increasing number of products to serve this special population coupled with increasing awareness about such diseases is expected to support growth of the global pediatric nutrition market. Furthermore, companies are focusing on development of products that may serve as nutrition enhancer or taste modifier, for the general population. Such products include ChocoMilk and Cal-C-Tose, which when added to milk enhance its nutritional value.

The four leading players holding a dominant position in the market are Reckitt Benckiser Group Plc, Nestlé S.A., Abbott Laboratories, and Groupe Danone, owing to a spree of market consolidation. Manufacturers are focusing on inorganic growth strategies such as mergers and acquisitions to strengthen their foothold in the global market. For instance, in 2012, Nestle S.A. acquired Pfizer Inc.’s infant nutrition business. In June 2017, Reckitt Benckiser Group Plc acquired Mead Johnson Nutrition, a leading player in pediatric nutrition.

Click To Reading More On Pediatric Nutrition Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Cellulite Treatment Market Foreseen to Grow Exponentially over 2026

Cellulite is a condition in which a person’s skin of their thighs, buttocks, and hips appears dimpled. Common names for cellulite include cottage cheese skin, orange-peel skin, hail damage, and the mattress phenomenon. This condition is commonly observed in women than in men due to the fat deposition in a normal women represents between 18% and 20% of body weight, whereas in men it represents only 10% to 15%.

Download The PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1773

According to 2015, article published by American Journal of Clinical Dermatology, around 80 and 90 percent of women are affected by cellulite at some point in their lives. Appearance of lumpiness beneath the skin due to fat deposits distorts and pushes the connective tissues, thus leads to the characteristic of cotton cheese appearance of the skin. Causes of cellulite are unidentified, however it seems to result from an interface between the fat layer and connective tissue in the dermatological layer, which is below the surface of the skin. Hormones such as noradrenaline, insulin, estrogen, prolactin, thyroid hormones play a significant role in cellulite development.

Cellulite Treatment Market – Dynamics

One of the major drivers propelling growth of the cellulite treatment market is the growing obese population. For instance, according to 2014 National Institute of Diabetes and Digestives and Kidney Diseases report, 2 in 3 adults (70.2 percent) were diagnosed with obesity in the U.S. Moreover, advancements in technology such as Cellulaze™ the world’s first and only minimally invasive medical device designed to eliminate cellulite which uses SideLight 3D side-firing technology to target the causes of cellulite beneath the skin, are boosting the growth of the cellulite treatment market size.

For instance, according to 2017, American Society of Plastic Surgeons report, around 1.8 million cosmetic surgical procedures were performed in 2017. Growing inclination towards achieving a slim body, lighter complexion, and better skin is also boosting demand for cosmetic treatment for cellulite. Furthermore, various technological advancement such as user-friendly pen shaped portable laser medical devices, is expected to boost growth of the market.

However, a major factor restraining growth of the cellulite treatment market is a popular alternative herbal massage treatment, which includes acupuncture, gua sha, and cupping techniques. Furthermore, high cost of cosmetic surgeries are expected to hamper the market growth.

Cellulite Treatment Market – Regional Insights

On the basis of the region, the global cellulite treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the dominant position in the global market, owing to adoption of the innovative medical products and treatments, For instance, in 2015, The Food and Drug Administration (FDA) approved Cellina, a non-invaise cellulite treatment. Moreover U.S is observing fast increase in aging population, is expected to create robust demand for aesthetic repair market services in the country. For instance, According to the American Society for Aesthetic Plastic Surgery (ASAPS) 2016 report, it was estimated that over 11 million aesthetic procedures were performed by board?certified specialists, of which 16.5% were surgical procedures and 83.5% were non?surgical procedures.

Asia Pacific is expected to witness significant growth in the market over the forecast period, owing to growing obese population in this region and increasing disposable income among the populace in the region.  According to 2017 Asian Development Bank Institute report Asia and the Pacific region is home to the largest absolute number of overweight and obese people, equivalent to about 1 billion.

Cellulite Treatment Market – Competitive Insights

Key players operating in the global cellulite treatment market include Tanceuticals, LLC., Nubway, Merz Pharma GmbH & Co. KGaA, Zimmer Aesthetics, Cymedics, Cynosure, Inc., Inceler Medikal Co. Ltd., and Syneron Medical Inc. Market players are focused towards collaborations and providing technologically advanced products to sustain their presence in the market.

Cellulite Treatment Market – Taxonomy

  • On the basis of treatment procedure, the global cellulite treatment market is segmented into:

Non-invasive, Minimally-invasive, Topical Treatment

Tubeless Insulin Pump Market Size, Share And Top Companies

Tubeless insulin pump is a portable pump, which is effective in controlling blood glucose level. Advancements in technologies of insulin pumps, which reduce the need for daily insulin injection doses is expected to boost growth of the tubeless insulin pump market over the forecast period. Omnipod, by Insulet Corporation is expected to drive the growth of insulin pumps in near future. Omnipod is a novel tubeless insulin pump, which displays blood glucose levels, schedules insulin delivery, and calculates optimal insulin dosage based on food database. Furthermore, Insulet Corporation has recently added additional features such as touchscreen and Bluetooth to Omnipod Dash system. Portability offered by these devices permits easy attachment and placements of the device on clothing or desired body parts, which is expected to drive growth of the tubeless insulin pump market.

Increasing funding by the government for studying various diseases including diabetes is also expected to fuel growth of the tubeless insulin pump market. For instance, in 2013, National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) funded several important studies on different types of artificial pancreas devices to help patients suffering from type 1 and type 2 diabetes and gestational diabetes. Insulin pumps have gained traction, owing to the rapid acting mechanism offering instant insulin delivery, user friendly interface, and flexible insulin delivery, which is expected to fuel growth of the tubeless insulin pump market over the forecast period.

Request For Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/1298

Increasing prevalence of diabetes due to obesity and increasing geriatric population is driving demand for tubeless insulin pump market. According to the World Health Organization, 2016, an estimated 422 million adults were suffering from diabetes globally. New technologies incorporated into tubeless insulin pump devices is leading to increasing demand for insulin pump devices worldwide. Market players are focused on developing new technologies in tubeless insulin pump devices, which can be used at home with ease and with accurate results, this in turn is expected to boost overall market growth during the forecast period. For instance, in 2016, in the U.K., Medtrum Technologies, Inc. launched S6 Easysense Disposable CGM System, which provides interstitial glucose levels in every two minutes and P6 Tubeless Patch Pump, which is ideal for type 2 diabetes management and gestational diabetes. It also allows monitoring of data using mobile app. However, high long-term cost associated with the use of tubeless insulin pump hampers the market growth. Compliance to therapy reduces over the time, owing to significant cost associated with daily use.

On the basis of geography, North America is expected to dominate the tubeless insulin pump market, followed by Europe, owing to high adoption rate for new technology and continuous government initiatives to create awareness regarding diabetes. For instance, in 2016, the American Diabetes Association (ADA) recommended diabetes education, training on the device, and providing support after prescription of Continuous Glucose Monitoring (CGM) and insulin pump. Market in Asia Pacific is lucrative in terms of market opportunities due to increase in research and development activities by various vendors and implementation of government initiatives for diabetic patients. For instance, in 2017, National Diabetes Services Scheme (NDSS) initiated by Australian Government funded Insulin Pump Programme to increase the affordability of insulin pumps to for people suffering from type 1 diabetes who don’t have access to private health insurance.

Major players operating in the tubeless insulin pump market include Medtronic Plc., Medtrum Technologies, Inc., Tandem Diabetes Care, Insulet Corporation, and Animas Corporation.

Click To Reading More On Tubeless Insulin Pump Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

The Future of Healthcare Pulmonary Drugs Market Is Closer Than You Think

Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated with the help of appropriate medication. This has led to intensification of efforts for development of effective and efficient pulmonary drugs and medications. Some of the pulmonary drugs are administered with the help of devices called nebulizers or inhalers.

The global pulmonary drugs market was valued at US$ 28.1 billion in 2016 and is expected to witness a robust CAGR of 8.1% over the forecast period (2017 – 2025).

Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2016, tobacco smoking is the primary cause of COPD leading to around 90% of COPD cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes consumption of bronchodilators, inhaled glucocorticoids, inhaled steroids, and other pulmonary drugs to relieve the disease symptoms, thereby propelling demand for pulmonary drugs. Tobacco is major cause of death and illness across the world. The number of smokers is consistent globally and does not have a drop since a past few years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma.

For instance, according to the Centers of Disease Control and Prevention (CDC) the average rate of smokers in 2012 was 1 in 5 people, which was reported to be constant in the Burden of Tobacco use in the U.S. released in 2015. North America dominates the global pulmonary drugs market, owing to the increasing prescriptions of Inhaled corticosteroids (ICS) and Long-acting beta-agonists (LABA) combinational products. According to Ontario Drug Policy Research Network, 2015, ICS+LABA combination products are the second-most commonly prescribed inhaled respiratory medications for all indications in Canada, with 1.1 million prescriptions dispensed in the fourth quarter of 2013, whereas, short-acting beta-agonists (e.g., salbutamol) are the most frequently prescribed inhaled respiratory medications in Canada with 1.8 million prescriptions dispensed in the same time period.

Request For Sample Copy:

https://www.coherentmarketinsights.com/insight/request-sample/1285

Supportive government and non-government initiatives to accelerate the market growth  

The government and non-government initiatives help patients to fight the diseases by providing sufficient medical care and education regarding the benefits of preventive measures as well as appropriate medications to curb the life threatening diseases such as COPD. For instance, in 2016, according to the World Health Organization (WHO), more than 90% of deaths were reported due to COPD in low and middle-income economies. Thus, the WHO initiated Global Alliance against Chronic Respiratory Diseases (GARD) with a vision to provide required medical treatments to patients suffering from chronic respiratory diseases in low and middle income economies. This provision demands a significant quantity of medication that is expected to propel the pulmonary drugs market.

Also, in 2015, the Bill and Melinda Gates Foundation granted a US$ 89 Mn funding to Novavax, to develop RSV F (Respiratory Syncytial Virus) Vaccine for pregnant women in low sourced countries as maternal immunization vaccine to protect respiratory infections in the children. Asia Pacific is expected to be the fastest growing region in the pulmonary drugs market, owing to the continuous marketing of new brands to consolidate and strengthen the sales of products by the manufacturers. For instance, in 2016, Lupin Limited and Novartis Healthcare Private Limited (NHPL) entered into a co-marketing agreement to promote Novartis’s Indacaterol / Glycopyrronium inhaler in India for treating COPD under the brand name of Loftair. The major players operating the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.

Click To Reading More On Pulmonary Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]

Cervical Total Disc Replacement Device Market Expansion to be Persistent During 2018 – 2026

Cervical total disc replacement devices is preferred in indications such as degenerative disc disorder etc. It is utilized in case there is no clinical improvement from pharmacological and physiotherapy intervention. There is another option against C-TDR which is traditionally used such as anterior cervical discectomy and fusion (ACDF). Cervical total disc replacement(C-TDR) carries advantage over the ACDF that it does not need use of bone graft therefore potential complications do not arise and there also less chances of failure. C-TDR also has low revision surgery rate. C-TDR preserves motion while acting as artificial disc in between two vertebrae. C-TDR comes with three designs such as constrained, semi constrained and unconstrained. They are made up of material such as stainless steel, cobalt, molybdenum and titanium. Biocompatible material such as PEEK are used in case metal over biocompatible type of C-TDR.

Innovative products by key players to drive growth of the cervical total disc replacement devices market

Several companies are launching the new products with better clinical safety and efficacy, which is expected to fuel growth of C-TDR market. Manufacturers are introducing new products with varying material and design aiming to provide better relief and simulation with natural cervical disc. In February 2018, Simplify Medical received the U.S. patent for innovative cervical motion preservation intellectual property (IP) portfolio. The Simplify Disc from Simplify Medical is anatomically designed with low height implants option till four mm. Therefore, it minimizes risk associated with radiation, optimize long-term durability, simplify implantation, and increase access to cervical disc replacement for patients with smaller anatomies.

Download The PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/1763

Market Dynamics

Major factor driving growth of the global cervical total disc replacement devices market is increasing prevalence of degenerative disc disorder and rise in aging population in the world. According data presented by American Academy of Orthopedic Surgeons in 2017, cervical radiculopathy (radiating pain from cervical disc degeneration), in which a compressed nerve initiates pain, numbness, or weakness in the neck and surrounding areas has an annual incidence of 107 in 100,000 for men and 64 in 100,000 for women in U.S. Cervical spondylitis also termed as osteoarthritis of cervical spine is also leading cause to drive the cervical total disc replacement devices market. Aging population is most vulnerable to cervical disk degeneration due worn out of disc with aging. Therefore aging population would drive the market during forecast period. According to statistics given by World Population prospect, globally there is more than 9 million people above age 60 which would increase to 1.3 billion by 2025

Key features of the study:

  • This report provides in-depth analysis of cervical total disc replacement devices market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new Fixator launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global cervical total disc replacement devices market based on the following parameters – company overview, financial performance, Fixator portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key players operating in the global cervical total disc replacement devices market include AxioMed Corporation, DePuy Synthes Spine, FH Orthopaedics, Globus Medical, LDR Holdings, Medicrea, Medtronic Sofamor Danek, NuVasive, Osimplant, Pioneer Surgical, Ranier Technology, Spinal Kinetics, Spinal Motion, and Stryker Corporation

Precise Analysis on Business Overview, Product Scope And Ongoing Gastrointestinal Stents Market Development 2026

Gastrointestinal Stents Market – Market Dynamics

Growth of the global gastrointestinal stents market is expected to be fuelled by increasing product launches with novel technology by key players in the market. For instance, in 2013, Cook Medical Inc. received U.S. Food and Drug Administration (FDA) for biliary stent, adding to the line of controlled-release gastrointestinal tract. Moreover, Evolution biliary stent incorporates patency design, to prevent migration of stent after its insertion. Furthermore, in 2012, Boston Scientific Corporation launched WallFlex, biliary Transhepatic Stent System for the treatment of benign biliary strictures. Companies are focusing on manufacturing stents with biodegradable material to eliminate stent removal procedures. However, implantable products are subjected to stringent regulations, and this is expected to hinder growth of the gastrointestinal stent market. Moreover, complication associated with gastrointestinal stent implantation is also expected to be major factor leading to low adoption of these device.

Download The PDF Brochure :  https://www.coherentmarketinsights.com/insight/request-pdf/1756

Increasing demand for minimally invasive procedures is expected to be a major factor driving growth of gastrointestinal stents market size. Gastrointestinal stenting is considered as minimally invasive therapy and is increasingly gaining popularity, owing to its advantages such as low risk of infection, less recovery time as compared to conventional open surgery procedures, and reduced hospital stay.

Increasing prevalence of urological and gastrointestinal disorders are propelling demand of gastrointestinal stents during the forecast period. According to Center for Disease Control and Prevention (CDC), in 2015, number of adults diagnosed in U.S. with ulcer in digestive tract are 14.7 million, comprising 6% of the total adult population. Moreover, according to American Cancer Society’s estimation for year 2018 suggests that 9,220 new cases of colon cancer are expected to be diagnosed in the U.S. Moreover, increasing number of patients with gastrointestinal tumors is also adding to patient pool that can be subjected to gastrointestinal stent implantation.

Stents are tubular device used for insertion in lumen such as esophagus, colon or blood vessel. Stents are safe and effective alternative to surgery or repetitive endoscopic procedures. Gastrointestinal stents are used to open bile ducts, esophagus, small bowel, and colon when blocked by large, cancerous tissue growth. Stents can be removable or permanently implantable based on the material used. The role of stenting is decreasing patients’ digestive tract obstruction. Moreover, advancement in technology has led to improvement in stent performance and reduced stent-induced complications to improve quality of life and this is expected to propel the gastrointestinal stent market growth.

Gastrointestinal Stents Market – Regional Analysis

Regional segmentation of Gastrointestinal Stents Market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America held the dominant position in the gastrointestinal stents market in 2017 and is expected to retain its dominance over the forecast period. This is owing to increasing number of intestinal cancer cases and favorable reimbursement policies in the region. For instance, in 2017, American Cancer Society estimated 4,000 to 6,000 cases each year in the U.S. for gastrointestinal stromal tumors.

Gastrointestinal Stents Market – Competitive Analysis

Major market players operating in the gastrointestinal stents market are Boston Scientific Corporation, Medtronic plc, Olympus Medical System, Cook Medical, Ella-CS, Endo-Flex, Diagmed Healthcare, Micro-Tech, W. L. Gore & Associates and Taewoong Medical Co., Ltd.